A neurologist's guide to inborn errors of metabolism (IEM) presenting with neurological symptoms — from newborn screening detection through the biochemical basis, clinical presentations, and evolving treatments of the major neurometabolic disorders affecting the nervous system.
Tags: Neurogenetics · Advanced
The core dichotomy in neurometabolic disease is small-molecule versus large-molecule IEM. Small-molecule IEMs involve water-soluble intermediary metabolites and include intoxication disorders (organic acidemias, urea cycle disorders, MSUD — toxicity from accumulating metabolites) and energy failure disorders (FAOD, mitochondrial disease, GLUT1 deficiency — fasting-provoked energy deficit). These are often treatable. Large-molecule IEMs are organelle-based storage disorders (lysosomal, peroxisomal, CDG) with progressive structural cellular damage that is usually irreversible. This framework explains why small-molecule IEMs present with episodic acute crises (reversible metabolite accumulation triggered by catabolism) while large-molecule IEMs present with insidious regression (irreversible cellular damage). Importantly, the same gene can produce different phenotypes based on residual enzyme activity — classic PKU vs mild hyperphenylalaninemia, infantile vs late-onset Pompe disease.
| Axis | Small-Molecule (Intoxication / Energy) | Large-Molecule (Organelle / Storage) |
|---|---|---|
| Biochemical Class | Aminoacidopathies, organic acidemias, UCD, FAOD | LSD, peroxisomal disorders, CDG |
| Clinical Tempo | Acute / episodic encephalopathy | Insidious regression |
| Systemic Clues | Hyperammonemia, acidosis, hypoglycemia | Coarse facies, HSM, cherry-red spot |
| MRI Pattern | Often normal early; BG edema in crisis | Symmetric leukodystrophy / atrophy |
| Reversibility | Often treatable — DON'T MISS | Generally irreversible |
| KY NBS | Many captured (PKU, MSUD, PA, MMA, GA1) | Few (Krabbe, Pompe, Fabry) |
Key Points
Newborn screening (NBS) by tandem mass spectrometry (MS/MS) of dried blood spots has revolutionized early identification of treatable IEM before symptom onset. The US Recommended Uniform Screening Panel (RUSP) includes >35 core conditions and 26 secondary conditions. MS/MS screens for amino acids and acylcarnitines in a single analysis. Expanded NBS programs in some states include dozens more conditions. A positive NBS is a screening result — confirmatory testing is always required before treatment.
Key Points
Several neurometabolic disorders have specific, highly effective treatments that prevent or reverse neurological damage if started early. Missing these diagnoses has catastrophic consequences. The neurologist's responsibility is to maintain a high index of suspicion, particularly in children with unexplained encephalopathy, seizures, regression, or movement disorder.
| Disorder | Mechanism | Key Clue | Don't-Miss Test | Treatment |
|---|---|---|---|---|
| GLUT1 (SLC2A1) | Glucose transport | Fasting seizures | CSF:serum glucose <0.45 | Ketogenic diet |
| PDE (ALDH7A1) | Antiquitin def. | Refractory neonatal seizures | Urine AASA | Pyridoxine |
| Biotinidase | Biotin recycling | Seizures / alopecia / rash / SNHL | Enzyme activity | Biotin |
| Creatine def. (GAMT / AGAT / SLC6A8) | Creatine synth./transport | ID / autism / seizures | Absent MRS creatine; urine Cr:creatinine | Creatine / ornithine |
| UCD (OTC / CPS1 / ASS1) | Urea cycle | Acute encephalopathy | Ammonia + PAA + urine orotic acid | N-scavengers / dialysis |
| MSUD | BCKDH def. | Encephalopathy, maple syrup odor | PAA (BCAA) | Leucine restriction |
| PA / MMA | Organic acidemia | Neonatal acidosis, hyperammonemia, BG stroke | UOA / acylcarnitine C3 | Protein restriction |
| Homocystinuria (CBS) | Methionine metab. | Marfanoid, lens dislocation, DVT | Total homocysteine | Pyridoxine trial |
| NPC (NPC1/NPC2) | Cholesterol trafficking | VSGP, ataxia, cognitive decline, HSM | Oxysterols | Miglustat |
| X-ALD (ABCD1) | Peroxisomal β-oxidation | Boys: behavioral / school decline + WM disease | VLCFAs | HSCT |
| PKU (PAH) | Phe hydroxylase | ID, seizures, tremor | PAA (phenylalanine) | Phe-restricted diet |
Key Points
Metabolic investigation follows a tiered approach from readily available serum and urine tests to more specialized CSF and enzymatic studies. The clinical presentation guides which metabolic pathways to prioritize. In acute metabolic crises — hyperammonemia, hypoglycemia, lactic acidosis — rapid diagnosis is essential for life-saving treatment.
| # | Presentation | Think… | Pearl |
|---|---|---|---|
| 1 | Acute encephalopathy + hyperammonemia | UCD / OA / FAOD | Treat ammonia, don't wait |
| 2 | Lactic acidosis, elevated L:P ratio | Mito / PDH | Single normal lactate doesn't exclude |
| 3 | Episodic ataxia / movement crisis | MSUD / OA / mito / UCD / GLUT1 | Timing relative to meals is critical |
| 4 | Regression after febrile illness | Intoxication IEM / Rett | Partial recovery favors IEM |
| 5 | Normal MRI + regression | Early IEM / GLUT1 / creatine / NKH | Normal MRI does NOT exclude IEM |
| 6 | Progressive leukodystrophy | MLD / Krabbe / X-ALD / Alexander / VWM | MRI pattern narrows the DDx |
| 7 | Cherry-red spot | GM1 / GM2 / NPA / sialidosis | Absence doesn't exclude LSD |
| 8 | HSM + neuro decline | NPC / Gaucher 3 / GM1 / MPS | NPC: VSGP classic but subtle |
| 9 | Refractory neonatal seizures | PDE / PNPO / NKH / biotinidase / MoCoD | Pyridoxine trial warranted |
| 10 | Infant hypotonia + neurodegeneration + hair/CT abnl | Menkes (ATP7A) | Low Cu/Cp; X-linked |
| 11 | Adolescent liver + BG signal + psych | Wilson (ATP7B) | KF rings absent in 50%; low Cp |
| 12 | ID + movement disorder + absent MRS creatine | Creatine deficiency (SLC6A8) | Urine Cr:creatinine ratio |
Key Points
Treatment approaches for IEM have expanded dramatically from dietary restriction to include cofactor supplementation, substrate reduction, enzyme replacement therapy (ERT), and increasingly gene therapy. The choice depends on the biochemical mechanism, organ involvement, and availability. Early treatment is critical — neurological damage in most IEM is partially or fully irreversible if accumulated before treatment.
Key Points
1. A newborn presents at 5 days of life with poor feeding, alternating hypo- and hypertonia, and a sweet maple syrup odor to the urine. Which amino acid is most specifically elevated and pathognomonic for this condition?
Maple syrup urine disease (MSUD) is caused by deficiency of branched-chain alpha-keto acid dehydrogenase, leading to accumulation of leucine, isoleucine, and valine. The presence of alloisoleucine — a stereoisomer of isoleucine formed by transamination — is pathognomonic for MSUD and is not found in other aminoacidopathies. Severe leucine neurotoxicity causes cerebral edema and encephalopathy if untreated.
2. A neonate presents with severe myoclonic seizures on day 1 of life. Seizures are refractory to phenobarbital and levetiracetam. The most important immediate diagnostic intervention is:
Pyridoxine (vitamin B6) should be given intravenously to any neonate with refractory seizures, as pyridoxine-dependent epilepsy (PDE, ALDH7A1/antiquitin deficiency) can cause refractory neonatal seizures that dramatically respond to pyridoxine. Missing this diagnosis results in ongoing seizures and developmental injury. The trial is safe (even if PDE is absent, IV pyridoxine at standard doses is not harmful to neonates) and should precede or accompany other workup.
3. A 3-year-old child has a CSF glucose of 25 mg/dL with a simultaneous blood glucose of 80 mg/dL (CSF:blood ratio 0.31). She has drug-resistant epilepsy, ataxia, and episodic dystonia. The most appropriate treatment is:
A CSF:blood glucose ratio <0.45 (normal >0.60) in the appropriate clinical context (drug-resistant epilepsy, movement disorder in a child) is diagnostic of GLUT1 deficiency syndrome (SLC2A1 mutations). The brain cannot import sufficient glucose, causing energy failure. The ketogenic diet bypasses this defect by providing ketones (3-hydroxybutyrate, acetoacetate), which are transported into the brain via MCT1 and serve as an alternative fuel. The diet is highly effective and is the standard of care.
4. A 17-year-old boy presents with progressive vertical gaze palsy, cerebellar ataxia, dysarthria, and cognitive decline over 3 years. He had unexplained neonatal jaundice. His sister has a similar presentation. Which diagnostic test is most specific for confirming the suspected diagnosis?
Niemann-Pick disease type C (NPC) is suggested by the combination of vertical supranuclear gaze palsy (a cardinal sign), progressive ataxia, cognitive decline, and the history of neonatal jaundice (common early feature). NPC1/NPC2 mutations impair cholesterol transport, causing accumulation of unesterified cholesterol and sphingolipids in lysosomes. The filipin staining assay of skin fibroblasts (which shows perinuclear free cholesterol accumulation) is the classic diagnostic test, though NPC1/NPC2 sequencing is increasingly the primary diagnostic approach.
5. Enzyme replacement therapy (ERT) is available for several lysosomal storage disorders but has limited efficacy for CNS manifestations. The primary reason is:
The major limitation of ERT for neurological LSDs (e.g., MPS, Fabry, Pompe) is that recombinant proteins (~60–80 kDa) do not cross the blood-brain barrier. IV-administered enzyme reaches liver, spleen, and bone marrow effectively but cannot access CNS neuronal and glial cells. This is why intrathecal or intracerebroventricular administration is being explored for MPS, and why gene therapy (AAV delivery directly to brain parenchyma) is a critical focus for neurological LSDs.